{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=35", "query": { "intervention": "cyclophosphamide", "page": 35 }, "page_size": 10 }, "pagination": { "page": 35, "page_size": 10, "total_count": 2804, "total_pages": 281, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=36&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=34&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T12:07:37.734Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00002546", "title": "Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "21 Years to 120 Years · Female only" }, "enrollment_count": 216, "start_date": "1993-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-02-11", "last_synced_at": "2026-10-31T12:07:37.734Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Gatos, California + 56 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Gatos", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002546" }, { "nct_id": "NCT00146562", "title": "Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Stage I Breast Cancer", "Stage II Breast Cancer" ], "interventions": [ { "name": "Darbepoetin Alfa", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harold J. Burstein, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2003-07", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2023-08-02", "last_synced_at": "2026-10-31T12:07:37.734Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Lowell, Massachusetts • Peabody, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Lowell", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00146562" }, { "nct_id": "NCT03136146", "title": "Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Burkitt Leukemia", "Recurrent Burkitt Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory Acute Lymphoblastic Leukemia", "Refractory Burkitt Leukemia", "Refractory Burkitt Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ofatumumab", "type": "BIOLOGICAL" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate Liposome", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 42, "start_date": "2017-08-09", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-31T12:07:37.734Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03136146" }, { "nct_id": "NCT00005988", "title": "Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myeloma" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "40 Years", "sex": "ALL", "summary": "Up to 40 Years" }, "enrollment_count": 5, "start_date": "2000-02", "completion_date": "2002-03-08", "has_results": false, "last_update_posted_date": "2017-04-04", "last_synced_at": "2026-10-31T12:07:37.734Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Minneapolis, Minnesota", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005988" }, { "nct_id": "NCT00006390", "title": "Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "alemtuzumab", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": null, "start_date": "2001-07-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-10-31T12:07:37.734Z", "location_count": 14, "location_summary": "Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 8 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006390" }, { "nct_id": "NCT04103879", "title": "US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Risk Hematological Malignancy", "Cord Blood Transplant" ], "interventions": [ { "name": "ECT-001-CB (UM171-Expanded Cord Blood Transplant)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ExCellThera inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 30, "start_date": "2020-11-13", "completion_date": "2026-02-28", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-10-31T12:07:37.734Z", "location_count": 2, "location_summary": "Aurora, Colorado • Seattle, Washington", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04103879" }, { "nct_id": "NCT01593020", "title": "Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 54, "start_date": "2012-08-03", "completion_date": "2020-11-04", "has_results": true, "last_update_posted_date": "2021-09-22", "last_synced_at": "2026-10-31T12:07:37.734Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01593020" }, { "nct_id": "NCT01490060", "title": "Fosaprepitant in Patients Receiving Ifosfamide-based Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sarcoma", "Chemotherapy-induced Nausea and Vomiting", "Effects of Chemotherapy", "Adverse Effects of Medical Drugs" ], "interventions": [ { "name": "Fosaprepitant", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "5HT3 receptor antagonist", "type": "DRUG" }, { "name": "Ifosfamide-based chemotherapy (AI)", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 47, "start_date": "2012-05", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2016-04-11", "last_synced_at": "2026-10-31T12:07:37.734Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01490060" }, { "nct_id": "NCT00413959", "title": "VELCADE,Rituximab,Cyclophosphamide and Decadron", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Lymphoma, B-Cell" ], "interventions": [ { "name": "VELCADE®", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Decadron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncology Specialists, S.C.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 12, "start_date": "2006-08", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2018-09-19", "last_synced_at": "2026-10-31T12:07:37.734Z", "location_count": 2, "location_summary": "Niles, Illinois • Park Ridge, Illinois", "locations": [ { "city": "Niles", "state": "Illinois" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00413959" }, { "nct_id": "NCT00074282", "title": "Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "pentostatin", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2005-04-14", "completion_date": "2018-05-06", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-10-31T12:07:37.734Z", "location_count": 143, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 112 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00074282" } ] }